Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kezar Life Sciences Inc (KZR)

Kezar Life Sciences Inc (KZR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 45,843
  • Shares Outstanding, K 7,323
  • Annual Sales, $ 0 K
  • Annual Income, $ -83,740 K
  • EBIT $ -66 M
  • EBITDA $ -69 M
  • 60-Month Beta 0.50
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.56

Options Overview Details

View History
  • Implied Volatility 345.87% (-33.85%)
  • Historical Volatility 13.72%
  • IV Percentile 62%
  • IV Rank 34.33%
  • IV High 941.28% on 04/14/25
  • IV Low 34.54% on 05/16/25
  • Expected Move (DTE 1) 0.09 (1.35%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 23
  • Volume Avg (30-Day) 61
  • Put/Call OI Ratio 0.61
  • Today's Open Interest 2,584
  • Open Int (30-Day) 2,325
  • Expected Range 6.22 to 6.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.39
  • Number of Estimates 2
  • High Estimate -1.30
  • Low Estimate -1.48
  • Prior Year -2.77
  • Growth Rate Est. (year over year) +49.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.05 +4.13%
on 11/28/25
6.37 -1.10%
on 12/10/25
+0.09 (+1.45%)
since 11/18/25
3-Month
3.53 +78.30%
on 10/07/25
6.40 -1.56%
on 10/21/25
+2.54 (+67.55%)
since 09/18/25
52-Week
3.53 +78.30%
on 10/07/25
6.95 -9.33%
on 12/26/24
+0.01 (+0.16%)
since 12/18/24

Most Recent Stories

More News
Kezar Life Sciences Reports Third Quarter 2025 Financial Results

Kezar Life Sciences, Inc . (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat immune-mediated diseases, today reported financial results...

KZR : 6.32 (+0.96%)
Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025

Kezar Life Sciences, Inc . (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced two...

KZR : 6.32 (+0.96%)
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives

Kezar Life Sciences, Inc . (Nasdaq: KZR, the Company), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today...

KZR : 6.32 (+0.96%)
Kezar Life Sciences to Participate in Two Upcoming Investor Conferences

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Chris...

KZR : 6.32 (+0.96%)
Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update

  Announced FDA removal of partial clinical hold on PORTOLA Phase 2a trial evaluating zetomipzomib for the treatment of patients with autoimmune hepatitis ...

KZR : 6.32 (+0.96%)
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis

Kezar Life Sciences, Inc . (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that...

KZR : 6.32 (+0.96%)
Karora Announces Agreement with Kalamazoo Resources to Unlock Lithium Exploration Value Through Creation of Kali Metals Limited

/CNW/ - Karora Resources Inc. (TSX: KRR) ("Karora" or the "Corporation") is pleased to announce it has entered into an agreement with Kalamazoo Resources...

KZR : 6.32 (+0.96%)
KZR.AX : 0.200 (-2.44%)
KRR.TO : 6.70 (+2.45%)
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Kezar Life Sciences, Inc ., (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that...

KZR : 6.32 (+0.96%)
Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial...

KZR : 6.32 (+0.96%)
Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the...

KZR : 6.32 (+0.96%)

Business Summary

Kezar Life Sciences, Inc. is a bio-technology company. It discovers and develops molecule therapeutics and medicines such as protein homeostasis for autoimmune disorders. The company's product pipeline consists of KZR-616 which is in clinical stage. Kezar Life Sciences, Inc. is headquartered in South...

See More

Key Turning Points

3rd Resistance Point 6.51
2nd Resistance Point 6.42
1st Resistance Point 6.34
Last Price 6.32
1st Support Level 6.17
2nd Support Level 6.08
3rd Support Level 6.00

See More

52-Week High 6.95
Last Price 6.32
Fibonacci 61.8% 5.64
Fibonacci 50% 5.24
Fibonacci 38.2% 4.84
52-Week Low 3.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar